Cargando…

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

BACKGROUND: We previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Chiaki, Kiyota, Naomi, Imamura, Yoshinori, Goto, Hideaki, Suto, Hirotaka, Chayahara, Naoko, Toyoda, Masanori, Ito, Yasuhiro, Miya, Akihiro, Miyauchi, Akira, Teshima, Masanori, Otsuki, Naoki, Nibu, Ken-ichi, Minami, Hironobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298753/ https://www.ncbi.nlm.nih.gov/pubmed/34307122 http://dx.doi.org/10.3389/fonc.2021.638123

Ejemplares similares

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report
por: Sai, Satoshi, et al.
Publicado: (2021)

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin
por: Funakoshi, Yohei, et al.
Publicado: (2016)

Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients
por: Fujiwara, Yutaka, et al.
Publicado: (2014)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra-Day Variation in Patients with Advanced Pancreatic Cancer
por: Fujiwara, Yutaka, et al.
Publicado: (2014)

The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer
por: Nishimura, Meiko, et al.
Publicado: (2016)

Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging
por: Nishimura, Meiko, et al.
Publicado: (2018)

Mediastinal Germ Cell Tumor Exhibiting a Discrepancy between Tumor Markers and Imaging: A Case Study
por: Takenaka, Kei, et al.
Publicado: (2015)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer
por: Koyama, Taiji, et al.
Publicado: (2021)

Intraoperative quantitative assessment of parathyroid blood flow during total thyroidectomy using indocyanine green fluorescence imaging ‐ surgical strategies for preserving the function of parathyroid glands
por: Iritani, Keisuke, et al.
Publicado: (2022)

Prognostic value of ALDH2 polymorphism for patients with oropharyngeal cancer in a Japanese population
por: Shinomiya, Hirotaka, et al.
Publicado: (2017)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
por: Fujiwara, Yutaka, et al.
Publicado: (2011)

Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report
por: Kimbara, Shiro, et al.
Publicado: (2021)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Incidence and spread pattern of lymph node metastasis from submandibular gland cancer
por: Tamagawa, Kotaro, et al.
Publicado: (2023)

Roles of skull base surgery and particle radiotherapy for orbital malignant tumors involving the skull base
por: Teshima, Masanori, et al.
Publicado: (2021)

Pharmacokinetic study of the oral fluorouracil antitumor agent S‐1 in patients with impaired renal function
por: Goto, Keiko, et al.
Publicado: (2019)

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer
por: Kiyota, Naomi, et al.
Publicado: (2015)

Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib
por: Taylor, Matthew H., et al.
Publicado: (2021)

Extent of neck dissection for patients with clinical N1 oral cancer
por: Kakei, Yasumasa, et al.
Publicado: (2020)

Oncolytic effect of Midkine promoter–based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891
por: Uehara, Natsumi, et al.
Publicado: (2020)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies
por: Minami, Hironobu, et al.
Publicado: (2020)

Secondary CIC-rearranged sarcoma responsive to chemotherapy regimens for Ewing sarcoma: A case report
por: Kimbara, Shiro, et al.
Publicado: (2021)

Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma
por: Kubota, Hikaru, et al.
Publicado: (2021)

Ibuprofen gargle for chemo- or Chemoradiotherapy-induced Oral Mucositis: a feasibility study
por: Ioroi, Takeshi, et al.
Publicado: (2020)

A laryngeal closure technique for the treatment of patients with head and neck cancer
por: Furukawa, Tatsuya, et al.
Publicado: (2019)

Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti‐Epidermal Growth Factor Receptor‐Induced Acne‐Like Rash: A Randomized Left‐Right Comparative Evaluation (APPEARANCE)
por: Chayahara, Naoko, et al.
Publicado: (2019)

Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial
por: Kiyota, Naomi, et al.
Publicado: (2022)

Clinical impact of a cytological screening system using cyclin D1 immunostaining and genomic analysis for the diagnosis of thyroid nodules
por: Teshima, Masanori, et al.
Publicado: (2019)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Prognostic factors after transoral resection of early hypopharyngeal cancer
por: Iritani, Keisuke, et al.
Publicado: (2021)

OK432 sclerotherapy for refractory chylous leakage after neck dissection
por: Hashimoto, Yuiko, et al.
Publicado: (2023)

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
por: Dotinga, Maaike, et al.
Publicado: (2022)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma
por: Groden, Phillip J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mea4sl7ugb20k6nk6o4dqi5r13